Clinical Trial Update: Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic Therapy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated celecoxib for age-related macular degeneration in patients receiving photodynamic therapy; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Celecoxib (Celecoxib)

Snippet

Sponsor: National Eye Institute (NEI) | Conditions: Macular Degeneration | Phase 2 | Status: COMPLETED